How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Sell
29
DOC Quote, Financials, Valuation and Earnings
Last price:
$20.21
Seasonality move
:
1.97%
Day range:
$19.98 - $20.39
52-week range:
$17.80 - $23.26
Dividend yield:
5.97%
P/E ratio:
57.69x
P/S ratio:
5.06x
P/B ratio:
1.68x
Volume:
3.5M
Avg. volume:
4.6M
1-year change:
7.68%
Market cap:
$14.1B
Revenue:
$2.7B
EPS (TTM):
$0.35
Analysts' Opinion
-
Consensus RatingHealthpeak Properties has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.68, Healthpeak Properties has an estimated upside of 22.22% from its current price of $20.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $22.00 representing 100% downside risk from its current price of $20.19.
Fair Value
-
According to the consensus of 14 analysts, Healthpeak Properties has 22.22% upside to fair value with a price target of $24.68 per share.
DOC vs. S&P 500
-
Over the past 5 trading days, Healthpeak Properties has overperformed the S&P 500 by 2.36% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Healthpeak Properties does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Healthpeak Properties has grown year-over-year revenues for 16 quarters straight. In the most recent quarter Healthpeak Properties reported revenues of $698M.
Earnings Growth
-
Healthpeak Properties earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Healthpeak Properties reported earnings per share of $0.01.
Enterprise value:
23.4B
EV / Invested capital:
--
Price / LTM sales:
5.06x
EV / EBIT:
42.19x
EV / Revenue:
8.65x
PEG ratio (5yr expected):
6.36x
EV / Free cash flow:
21.82x
Price / Operating cash flow:
12.76x
Enterprise value / EBITDA:
14.50x
Gross Profit (TTM):
$1.6B
Return On Assets:
1.26%
Net Income Margin (TTM):
9%
Return On Equity:
2.75%
Return On Invested Capital:
1.42%
Operating Margin:
17.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2.1B | $2.2B | $2.7B | $553.7M | $698M | |
| Gross Profit | $1.2B | $1.3B | $1.6B | $329.3M | $421M | |
| Operating Income | $356.6M | $433.9M | $471.2M | $119.2M | $122.6M | |
| EBITDA | $1.4B | $1.3B | $1.6B | $301.3M | $341.7M | |
| Diluted EPS | $0.92 | $0.56 | $0.35 | $0.13 | $0.01 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3B | $713.4M | $605M | $561.3M | $986.1M | |
| Total Assets | $15.9B | $15.3B | $15.8B | $15.7B | $19.9B | |
| Current Liabilities | $1.3B | $1.9B | $1.8B | $1.4B | $875.3M | |
| Total Liabilities | $8.6B | $8.1B | $8.5B | $8.8B | $10.9B | |
| Total Equity | $7.3B | $7.1B | $7.3B | $6.9B | $9.1B | |
| Total Debt | $6.3B | $6.2B | $6.5B | $6.9B | $8.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $900.3M | $956.2M | $1.1B | $231.2M | $283.5M | |
| Cash From Investing | -$876.3M | -$576.8M | -$113.8M | -$215.7M | -$233.8M | |
| Cash From Financing | -$116.5M | -$337.3M | -$941.4M | $39.5M | -$107.5M | |
| Free Cash Flow | $900.3M | $956.2M | $1.1B | $231.2M | $283.5M | |
DOC
Sector
Market Cap
$14.1B
$1B
Price % of 52-Week High
86.8%
80.78%
Dividend Yield
5.97%
3.28%
Shareholder Yield
4.37%
3.41%
1-Year Price Total Return
7.68%
-2.11%
Beta (5-Year)
1.141
0.886
Dividend yield:
5.97%
Annualized payout:
$1.20
Payout ratio:
326.88%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$20.27
200-day SMA
Sell
Level
$21.06
Bollinger Bands (100)
Sell
Level
19.87 - 21.47
Chaikin Money Flow
Sell
Level
-5.7M
20-day SMA
Sell
Level
$20.33
Relative Strength Index (RSI14)
Sell
Level
48.66
ADX Line
Sell
Level
4.72
Williams %R
Neutral
Level
-72.093
50-day SMA
Sell
Level
$20.25
MACD (12, 26)
Buy
Level
5.52
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Sell
Level
-18.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Sell
CA Score
(Annual)
Level (-0.6614)
Buy
Beneish M-Score
(Annual)
Level (-2.3333)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.3412)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Healthpeak owns a diversified healthcare portfolio of approximately 697 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.
Stock Forecast FAQ
In the current month, DOC has received 9 Buy ratings 5 Hold ratings, and 0 Sell ratings. The DOC average analyst price target in the past 3 months is $24.68.
-
Where Will Healthpeak Properties Stock Be In 1 Year?
According to analysts, the consensus estimate is that Healthpeak Properties share price will rise to $24.68 per share over the next 12 months.
-
What Do Analysts Say About Healthpeak Properties?
Analysts are divided on their view about Healthpeak Properties share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Healthpeak Properties is a Sell and believe this share price will drop from its current level to $22.00.
-
What Is Healthpeak Properties's Price Target?
The price target for Healthpeak Properties over the next 1-year time period is forecast to be $24.68 according to 14 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is DOC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Healthpeak Properties is a Buy. 9 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DOC?
You can purchase shares of Healthpeak Properties via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Healthpeak Properties shares.
-
What Is The Healthpeak Properties Share Price Today?
Healthpeak Properties was last trading at $20.21 per share. This represents the most recent stock quote for Healthpeak Properties. Yesterday, Healthpeak Properties closed at $20.19 per share.
-
How To Buy Healthpeak Properties Stock Online?
In order to purchase Healthpeak Properties stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 31
Ajinomoto [AJINY] is down 2.15% over the past day.
Sell
40
RGC alert for Mar 31
Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.
Buy
69
AGX alert for Mar 31
Argan [AGX] is down 4.98% over the past day.
